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OBJECTIVE: Chemotherapy doublets have been widely
tested to treat non-small-cell lung cancer (NSCLC).
However, little is known about the major cost determi-
nants for the various doublets. This study examines major
cost implications of four novel treatment regimes in
France. METHODS: Chemotherapy and medical
resource utilisation was based on Schiller et al (2002), 
a prospective randomised, controlled trial of gemci-
tabine/cisplatin (Gem/Cis), paclitaxel/cisplatin (Pac/Cis),
paclitaxel/carboplatin (Pac/Carbo) and docetaxel/cis-
platin (Doc/Cis) totalling 1207 patients. These trial data
were combined with unit cost data from Assistance
Publique des Hopitaux de Paris 2000. Clinical trial data
showed equivalent efﬁcacy for overall survival and 
progression-free survival, with a trend in favour of
Gem/Cis. Consequently, cost-minimisation was the
appropriate form of economic evaluation. RESULTS:
Chemotherapy acquisition was the major cost factor
across all regimens with Gem/Cis patients having the
lowest costs compared to patients treated with Pac/Cis,
Pac/Carbo or Doc/Cis. Chemotherapy acquisition costs
ranged from €3163 for the Gem/Cis doublet to €9367 for
the Pac/Carbo combination. The cost of hospitalisations
for adverse events were greatest in patients treated with
Gem/Cis, as were the costs for the administration of 
the chemotherapy. The costs of other medical resources
including blood transfusions, concomitant medications
and health care professional visits were relatively small
and similar across all the treatment groups. In total, the
higher chemotherapy acquisition costs of the taxane
agents were not offset by the lower administration and
hospitalisation costs. Patients treated with Gem/Cis 
were associated with lower total treatment costs (€7048)
than those treated with Pac/Cis (€8694), Pac/Carbo
(€11893) and Doc/Cis (€7135). CONCLUSIONS: The
cost-minimisation approach used is a conservative one
since, a trend exists for longer progression free survival
with Gem/Cis, whereas this analysis assumes equal efﬁ-
cacy. This analysis supports the economic argument in
favour of the Gem/Cis combination over the other three
regimes from a cost-minimisation perspective.
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OBJECTIVE: This study examines the cost of various
platinum based chemotherapy regimes in the treatment 
of advanced non-small cell lung cancer (NSCLC) from 
the perspective of the Spanish health care system.
METHODS: A retrospective economic analysis was con-
ducted based on two published phase III randomised 
controlled trials of gemcitabine/cisplatin (GC) and other
regimens. Comella et al (2000) compared GC with
vinorelbine/cisplatin (VC); Schiller et al (2002) compared
GC with paclitaxel/cisplatin (PC), carboplatin/paclitaxel
(CP) and docetaxel/cisplatin (DC). As the efﬁcacy of the
compared regimens may be considered equivalent, a 
cost-minimisation analysis was conducted. Only direct
costs were included in the analysis. Costs were compared
across four main resource categories: chemotherapy
acquisition, drug administration, hospitalisations and
other medical resources. Spanish health care unit costs
were drawn from the literature and public sources.
RESULTS: The economic analysis applied to the Comella
trial indicated that the total cost of the GC (€4097)
regime was 84% of the VC (€4899) regime. When applied
to the Schiller et al study, the total cost of the GC (€5154)
regime was only 79% of the total cost for the DC (€6512)
regime, 76% of the total cost of the PC (€6746) regime
and 53% of the total cost of the CP (€9750) regime.
CONCLUSIONS: For treatment of advanced NSCLC in
Spain, GC show cost savings potential compared to with
VC, PC, CP, and DC. The cost of acquiring chemother-
apy is not the only direct cost that should be considered
when treating patients with chemotherapy, drug admini-
stration, hospitalisations and other medical resources are
costs that should be considered.
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OBJECTIVES: In clinical trials zoledronic acid has shown
higher efﬁcacy in HCM treatment than pamidronate, cur-
rently the drug most widely used. This study evaluated
both treatment options from an economic perspective.
METHODS: The main outcome measures were incre-
mental cost-efﬁcacy ratios of zoledronic acid 4mg vs.
pamidronate 90mg perfusions. From the hospital 
perspective, data on direct, short-term variable resources
consumed during drug administration were collected
from seven Spanish hospitals using a structured ques-
tionnaire. Efﬁcacy data (rate and duration of complete
response) were extracted from controlled clinical trials.
RESULTS: In total the participating hospitals treated 271
patients/year (93% in outpatient infusion sites). Apart
from a price difference of €65.97, differences in resource
consumption were related to perfusion times and subse-
quent demand on personnel, and certain supplies. Time
